(2S,3R,4E)-3-O-benzoyl-2-hexadecanamido-4-octadecene-1,3-diol | 4201-55-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S,3R,4E)-3-O-benzoyl-2-hexadecanamido-4-octadecene-1,3-diol
• 英文别名: N-palmitoyl-3-O-benzoyl-D-erythro-sphingosine；Erythro-N-palmitoyl-3-O-benzoyl-D-sphingosin；[(E,2S,3R)-2-(hexadecanoylamino)-1-hydroxyoctadec-4-en-3-yl] benzoate
• CAS: 4201-55-2
• 化学式: C₄₁H₇₁NO₄
• 分子量: 642.019
• InChiKey: JRPXPAYLPZULEJ-QMESAKPFSA-N

物化性质

• 沸点：
  743.6±60.0 °C(Predicted)
• 密度：
  0.958±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  15.1
• 重原子数：
  46
• 可旋转键数：
  33
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2S,3R,4E)-3-O-benzoyl-2-hexadecanamido-4-octadecene-1,3-diol 在 tin(II) trifluoromethanesulfonate 、 4 A molecular sieve 、 sodium methylate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 1,1,3,3-四甲基脲 作用下， 以 吡啶 、 甲醇 为溶剂， 反应 34.5h， 生成 (2S,3R)-N-palmitoyl-1-O-<6'-O-<2''-(N-methyl-N-<2''',2''',2'''-trichloroethoxycarbonyl>amino)ethylphosphonyl>-β-D-galactopyranosyl>-D-sphingosine
  参考文献：
  名称：

  海洋蜗牛涡轮角ut中发现的磷酸鞘氨醇糖脂的合成

  摘要：

  在海洋蜗牛Turbo cornutus中发现的膦酰基鞘氨醇糖脂（1）是由半乳糖作为手性前体，通过脑苷（7）与受保护的膦酸的缩合合成而成，使用DEC作为关键步骤。

  DOI：

  10.1016/s0040-4039(00)86684-8
• 作为产物：
  描述：

  (2S,4R,5R)-4-[(1E)-1-十五碳烯-1-基]-2-苯基-1,3-二恶烷-5-醇 在 吡啶 、 咪唑 、 盐酸 、 sodium azide 、 四丁基氟化铵 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.5h， 生成 (2S,3R,4E)-3-O-benzoyl-2-hexadecanamido-4-octadecene-1,3-diol
  参考文献：
  名称：

  Syntheses of D-erythro-1-deoxydihydroceramide-1-sulfonic acid and phosphonosphingoglycolipid found in marine organisms via a common precursor

  摘要：

  DOI：

  10.1016/s0040-4020(01)80087-9

文献信息

• Sphingolipids and Glycerolipids. Part II. Syntheses of Two Pairs of Enantiomeric C18-Sphingosines and a Palmitoyl Analogue of Gaucher Spleen Glucocerebroside.
  作者：Hirotaka SHIBUYA、Keiko KAWASHIMA、Norihiko NARITA、Masahiko IKEDA、Isao KITAGAWA

  DOI：10.1248/cpb.40.1154

  日期：——

  Sixteen kinds of chiral C4-epoxides [(-)-10a-d, (+)-10a-d, (-)-11a-d, (+)-11a-d], which are synthons in our synthetic strategy for complex lipids, have been prepared from (2Z)-2-butene-1, 4-diol (6) by employing a Sharpless asymmetric epoxidation. By using the chiral C4-epoxides [(+)-10a, (-)-10a, (-)-11a, (+)-11a] as starting compounds, two pairs of enantiomeric (D-erythro, L-erythro, D-threo, and L-threo)-C18-sphingosines (1, 2, 3, 4) have been synthesized via a regioselective ring-opening of the epoxide ring with azide anion followed by reduction of the azide group to an amino group and a Wittig reaction. Furthermore, D-erythro-C18-sphingosine (1) has been converted to a palmitoyl analogue (5a) of Gaucher spleen glucocerebroside (5) through a reaction pathway including successive condensations with palmitic acid and D-glucose.

  已合成十六种手性C4-环氧化物 [(-)-10a-d, (+)-10a-d, (-)-11a-d, (+)-11a-d]，这些化合物是我们合成复杂脂质策略中的合成子，通过使用Sharpless不对称环氧化反应，从(2Z)-2-丁烯-1, 4-二醇(6)制备而成。利用手性C4-环氧化物 [(+)-10a, (-)-10a, (-)-11a, (+)-11a] 作为起始化合物，通过环氧环的区域选择性开环反应与叠氮阴离子结合，随后将叠氮基团还原为氨基，并进行Wittig反应，合成了两对对映异构体（D-赤藓糖，L-赤藓糖，D-反式，L-反式）C18-鞘氨醇（1, 2, 3, 4）。此外，D-赤藓糖-C18-鞘氨醇（1）通过与棕榈酸和D-葡萄糖的连续缩合反应途径转化为高雪氏脾脏葡萄糖苷脂（5）的棕榈酰类似物（5a）。
• The total synthesis of ganglioside GM3
  作者：Richard I. Duclos

  DOI：10.1016/s0008-6215(00)00121-x

  日期：2000.10

  beta-Gal-(1'' --> 3'/4')-GlcNAc alpha-(2''' --> 3'')-sialyltransferase enzyme, and was evaluated as a synthetic intermediate to ganglioside GM3. The chemical total synthesis of ganglioside GM3 was performed on one of the largest scales yet reported. The highlights of this synthesis include minimizing the steps necessary to prepare the lactosyl acceptor as a useful anomeric mixture, which was present in

  审查了神经节苷脂GM3（NeuAc alpha3Gal beta4Glc beta1Cer）的先前合成，并研究了化学酶和化学全合成方法。在化学酶学方法中，（2S，3R，4E）-5'''-乙酰基-α-神经氨酸-（2'''-> 3''）-β-吡喃半乳糖基-（1''-> 4'使用重组β-Gal-（1''-> 3'可以轻松制备）-β-吡喃葡萄糖基-（1'-> 1）-2-叠氮基-4-十八碳烯1，，3-二醇（azidoGM3） / 4'）-GlcNAcα-（2'''-> 3''）-唾液酸转移酶，被评估为神经节苷脂GM3的合成中间体。神经节苷脂GM3的化学全合成以迄今报道的最大规模之一进行。该合成的亮点包括最小化制备作为有用的异头混合物的乳糖基受体所必需的步骤，对于与已知神经氨酰基供体的高度区域选择性和相当立体选择性的唾液酸化，过量存在以得到被保护的GM3三糖。合成方法通过充分表征的GM3三糖三氯乙亚氨
• NOVEL SYNTHESIS INTERMEDIATES FOR OBTAINING DERIVATIVES OF SPHINGOSINES, CERAMIDES AND SPHINGOMYELINS WITH GOOD YIELDS
  申请人：M2I DEVELOPMENT

  公开号：US20160083335A1

  公开（公告）日：2016-03-24

  The subject matter of the present invention is the novel molecules of formulae E, E′ and F. These molecules prove to be synthesis intermediates that are very advantageous for the manufacture of derivatives of sphingosine or of ceramides functionalized in position 1, with good yields, in which R 1 and R 2 are fatty chains, R 3 is an alkyl group and R 4 is a protective group for alcohol functions. Another subject of the invention is the use of the intermediates of type F for converting same into intermediates of type G, by means of reduction in the presence of lithium borohydride. The G molecules are precursors that are known to make it possible to obtain sphingolipids or sphingomyelin.

  本发明的主题是公式E、E'和F的新型分子。这些分子被证明是合成中间体，非常有利于制造在1位功能化的鞘氨醇衍生物或鞘氨醯胺衍生物，收率良好，其中R1和R2是脂肪链，R3是烷基基团，R4是醇功能的保护基团。本发明的另一个主题是将F型中间体转化为G型中间体的用途，通过在锂硼氢化铝的存在下进行还原。G分子是已知的前体，可以用来获得鞘脂类或鞘磷脂。
• METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS
  申请人：CERENIS THERAPEUTICS HOLDING SA

  公开号：US20140316154A1

  公开（公告）日：2014-10-23

  The present invention includes methods for the synthesis of sphingomyelins and dihydrosphingomyelins. The present invention also includes methods for the synthesis of sphingosines and dihydrosphingosines. The present invention further includes methods for the synthesis of ceramides and dihydroceramides.

  本发明涉及合成鞘磷脂和二氢鞘磷脂的方法。本发明还涉及合成鞘氨醇和二氢鞘氨醇的方法。本发明还涉及合成鞘醇和二氢鞘醇的方法。
• Synthesis of α-l-rhamnosyl ceramide and evaluation of its binding with anti-rhamnose antibodies
  作者：David E. Long、Partha Karmakar、Katherine A. Wall、Steven J. Sucheck

  DOI：10.1016/j.bmc.2014.08.002

  日期：2014.10

  An α-L-rhamnosyl ceramide (1, α-L-RhaCer) has been prepared that was recognized by anti-L-rhamnose (anti-Rha) antibodies. During these studies we explored the use of an α-L-rhamnosyl thioglycoside and a trichloroacetimidate as a glycosyl donors. Subsequently, the acceptors desired for glycosylation, 3-O-benzoylazidosphingosine or 3-O-alloxycarbonylsphingosine, were prepared from D-xylose. The thioglycoside donor, 2,3,4-tri-O-acetyl-1-(4-tolyl)thio-α-L-rhamnopyranoside, and the trichloroacetimidate donor, 2,3,4-tri-O-acetyl-1-(2,2,2-trichloroethanimidate)-α-L-rhamnopyranoside, were synthesized in 50% and 78% yield overall, respectively. The synthesis of the glycosylation acceptor employed an addition-fragmentation olefination that was successfully carried out in 53% yield. With the successful synthesis of key intermediates, α-L-RhaCer (1) was prepared without any insurmountable obstacles. Anti-Rha antibodies were prepared in BALB/c mice by immunizing them with rhamnose-ovalbumin (Rha-Ova) with Sigma Adjuvant System (SAS) and the anti-L-Rha antibodies were isolated from the blood sera. Liposomes and EL4 tumor cells were used as model systems to demonstrate the ability of 1 to insert into a lipid bilayer. The interaction of the liposomes or the EL4 cells with α-L-RhaCer (1) and anti-Rha antibodies were investigated by fluorescence microscopy and flow cytometry, respectively, to confirm the ability of glycolipid 1 to be displayed on the tumor cell surface as well as the ability to be recognized by anti-Rha antibodies.